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From the beginning, the COVID-19 pandemic turned
out to be a huge challenge and burden for medical services [1]. Currently, humanity is dealing with
a new wave of the virus that has evolved and presents
a new challenge, mainly due to its ability to avoid
immune surveillance. Indeed, our main line of defense — vaccines — may be compromised. Omicron
variants are characterized by an evolutionary force
unprecedented so far. Among the several sublines
that have already emerged, the BA.5 strain exhibit
higher transmissibility and demonstrates a worrisome
immune evasion. According to several laboratory investigations, vaccination-induced antibodies are less
successful at preventing BA.4/5 strains infection as
opposed to the infections following BA.1/BA.2 strains
exposure [2–6]. The hyper contagious BA.5 variant is
mainly responsible for the rise in hospital and intensive care unit utilization we are facing in the current
times. Within a few months, BA.5 outperformed its
forerunners and became the dominant strain in the
United States (US). According to the most recent

statistics provided by the Centers for Disease Control
and Prevention (CDC), this subvariant was responsible
for nearly 2 out of every 3 new COVID-19 infections
in the US (3.07.2022–9.07.2022) [7].
The BA.4/5 variants are four times more resistant
to sera from vaccinated individuals than other omicron strains [8]. The neutralizing antibody response
induced by BA.1 infection, seems to be narrower
than anticipated, leaving patients vulnerable to immune evading variants like BA.4/BA.5 [9]. As a result,
repeated Omicron infections may affect previously
(triple) vaccinated patients. Even patients who developed hybrid immunity via vaccination and prior infection (from Omicron BA.1 or other variants)
fail to render BA.4/BA.5 ineffective. This has been
linked to the spike mutations L452R and F486V. The
new BA.2.75 variant, a sub lineage of the Omicron
BA.2 that was first detected in India and has been
discovered in other countries, including Japan, Germany, the United Kingdom, Canada, the U.S, Australia, and New Zealand [10]. This may pose a serious
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threat to humankind. Compared to its parent strain,
eight more spike protein mutations are present in
this strain. Because of the location of these mutations, it is likely that BA.2.75 may overcome immune
defense against BA.2 [10]. The ability of BA.2.75 to
evade immunity appears to be confirmed by the
fact that it was able to expand in at least ten distinct
areas of India, despite the previous experience of
a BA.2 wave. Immune escape might be made worse
by mutations of the novel BA.2.75 sub-variant than
what we are now witnessing with BA.5 and BA.4,
sub-variants known to escape immunity after both
vaccination and prior infection.
The BA.5 variation essentially depicts how this
virus evolved to be more infectious and to get beyond human immune defenses against infection,
immunization, or both. People have relatively little
defense against BA.5 for a mild to moderate illness,
regardless of vaccination status, prior infection, or
prior infection and vaccination. However, protection
against the most severe forms seems to be maintained among healthy individuals as demonstrated
by the relatively low incidence of hospitalization, ICU
admissions, and death in the number of cases.
Protective measures might also be adapted
when dealing with new variants. The Omicron variant (B.1.1.529) has a shorter incubation time and
a greater transmission rate than earlier versions [11].
As a result, the CDC advised a shortening of the
isolation period for infected individuals from 10 to
5 days following onset of symptoms (or positive
test) followed by a 5-day mask wear. When analyzing the replicative capacity of SARS-CoV-2 obtained
from swabs of infected patients researchers found
that the median time from the initial positive PCR
test to the absence of viral infectivity in culture was
4 days (3 to 5) for Delta strain and 5 days (3 to 9)
for Omicron. The median time from symptom onset
(or initial positive PCR testing) from sterile culture
was 6 days (4 to 7) for Delta and 8 days (5 to 10) for
Omicron. Considering those observations, it appears
that compared to the Delta variant, the infectivity
of Omicron lasts longer — on average by at least
2 days (5–10 days). Therefore, the 5-days isolation
period seems too short to restrain virus spreading
when infected with an Omicron strain. Therefore,
the 5-days isolation period seems too short to restrain virus spreading when infected with an omicron strain. In this perspective, strict application of
health precautions and physical distancing measures
seems mandatory to restrain virus spreading [12].
140

It’s important to keep in mind that vaccinations
are based on the original Wuhan strain. Therefore,
the vaccine’s immunity may not confer enough protection to new variants. Due to the rapid ability
of SARS-CoV-2 to evolve and evade, the pharma
industry may not be able to develop and provide tailored vaccines fast enough. On this topic, salvation
may come from pan-coronavirus vaccines, several of
which are in development. Those pan-coronaviruses
vaccines may ward off future variants and prevent
upcoming waves in an optimistic scenario. However,
the emergence of possible antigenic imprinting (or
Hoskins effect), a failure of the immune system to
mount sufficient effective immune response when
encountering a slightly different version of a pathogen, must be taken into consideration [13].
These symptoms will primarily be catarrhal and
cold-related. This does not change the fact that
owing to the virus’s enhanced contagiousness, quite
a lot of people may end up needing hospitalization.
Due to their capacity to infect individuals who had
developed resistance to earlier iterations of Omicron and other variants, BA.4/5 appears to have
developed. The rise of BA.4/5, as well as their inevitable decline, will be largely influenced by population resilience because most of the rest of the
world outside of Asia is doing little to control SARSCoV-2. However, we are unable to predict what
may happen along the way with potential new varieties. We are also unaware of any more changes
that may be far deadlier, especially given the virus’s
quick mutations — on the bright side, there is less
likelihood of a wholly new variety emerging because
of infection the longer the Omicron and its branches
continue to predominate.
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